CLINICAL EVALUATION OF PEPTICHEMIO

Google Scholar
  • 1 January 1979
    • journal article
    • research article
    • Vol. 63  (3) , 385-389
Abstract
Peptichemio is a peptide complex of m-L-phenylalanine mustard. A clinical evaluation of this agent was conducted in 116 patients, of whom 104 were evaluable for toxicity and response. The majority of patients had soil tumors. The drug was administered i.v. daily for 3 days at doses of 20-75 mg/m2 per day, with courses repeated at 3-4 wk intervals. The optimal dose schedule appears to be 45 mg/m2 per day for 3 days. The major side effects were cumulative myelotoxicity, phlebitis and mild nausea and vomiting. No other major organ toxicity was observed. The partial remission rate was 7%. Most patients had received an alkylating agent as part of their previous therapy. There were 7 partial responses and 4 less than partial responses achieved in patients with melanoma, lymphoma and gastrointestinal, genitourinary, breast, and head and neck carcinomas. Responses lasted 4-36 wk.

This publication has 1 reference indexed in Scilit: